New Alzheimer S Drug Brings Hope And Tough Choices For Patients Caregivers
The arrival of lecanemab comes with some big caveats, however. The drug has significant health risks, including bleeding and brain swelling. It’s expensive—drug manufacturer Eisai estimates the annual price of treatment would be somewhere between $9,249 and $35,605, and it’s unclear what insurance will cover. And the drug has only a modest effect on the debilitating progress of Alzheimer’s. Some scientists are also having second thoughts about the strategy that led to lecanemab—namely, trying to slow Alzheimer’s solely by inhibiting the buildup of beta-amyloid, a protein that accumulates in the brain cells to form plaques....